Tersolisib is named as an intervention in 3 current clinical trials in our USA, Ireland, UK and China registers. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Eli Lilly and Company. The most-studied condition is Breast Neoplasms.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336 · Breast Neoplasms, Neoplasm Metastasis
|
Phase 3 | Recruiting | Eli Lilly and Company | Ireland, UK, USA, China |
|
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139 · ClinicalTrials.gov ↗ · Breast Cancer, Solid Tumors, Adult
|
Phase 1/2 | Recruiting | Eli Lilly and Company | Ireland, USA |
|
A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants
NCT07662798 · ClinicalTrials.gov ↗ · Healthy
|
Phase 1 | Active, closed | Eli Lilly and Company | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
| Clinical trials in Ireland | 2 | 2 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, Ireland, UK and China registers name Tersolisib (also registered as LY4064809) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA, 2 with sites in Ireland, 1 with sites in UK and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Eli Lilly and Company. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tersolisib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tersolisib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tersolisib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.